131I-APAMISTAMAB-LED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT DEMONSTRATES SURVIVAL BENEFIT AND OVERCOMES HIGH-RISK TP53 MUTATIONS IN PATIENTS WITH R/R AML

ADDITION OF NIVOLUMAB TAILORED BY EXPANSION OF CAR-T CELLS IN PATIENTS WITH PROGRESSIVE DLBCL AT LYMPHODEPLETION – A PHASE 2, PROSPECTIVE INTERVENTIONAL STUDY – FINAL ANALYSIS

CLINICAL EXPERIENCE OF TABELECLEUCEL IN EPSTEIN–BARR VIRUS-POSITIVE POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (EBV+ PTLD) INVOLVING THE CENTRAL NERVOUS SYSTEM

EFFICACY AND SAFETY OF RECOMBINANT ERWINIA ASPARAGINASE (JZP458) IN ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL)/LYMPHOBLASTIC LYMPHOMA (LBL): COMPLETE FOLLOW-UP OF THE CHILDREN’S ONCOLOGY GROUP AALL1931 STUDY

FINAL RESULTS OF PROSPECTIVE CLINICAL TRIAL EVALUATING OUTPATIENT ADMINISTRATION OF AXICABTAGENE CILOLEUCEL IN HIGH-GRADE B CELL LYMPHOMA

HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS OF OLDER AGE WITH AML IN FIRST COMPLETE REMISSION: RESULTS OF A RANDOMIZED PHASE III TRIAL OF THE EBMT

LOCOMMOTION: A PROSPECTIVE, OBSERVATIONAL, MULTINATIONAL STUDY OF REAL-LIFE CURRENT STANDARDS OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA – FINAL ANALYSIS AT 2-YEAR FOLLOW-UP

PHASE 2 CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL IN MULTIPLE MYELOMA AND 1–3 PRIOR LINES (COHORT A) AND WITH EARLY RELAPSE AFTER FRONTLINE TREATMENT (COHORT B)

PHASE I/II STUDY ON INFUSION OF ALLOREACTIVE OR EX VIVO IL-15 STIMULATED NK CELLS AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH ACUTE LEUKEMIA